Search for: "Apotex, Inc. " Results 1 - 20 of 674
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
The Use of Mandated Public Disclosures of Clinical Trials as Prior Art Against Study Sponsors
16 Apr 2024, 8:42 am by Holman
Apotex Inc., 939 F.3d 1375 (Fed. [read post]
Patently-O - https://patentlyo.com
More on Reasonable Expectation of Success from the Federal Circuit
19 Mar 2024, 8:54 am by Dennis Crouch
Apotex, Inc., 480 F.3d 1348 (Fed. [read post]
Patently-O - https://patentlyo.com
Pfizer v. Sanofi: Applying the Results-Effective Variable Doctrine in Obviousness Analysis
5 Mar 2024, 10:23 am by Dennis Crouch
Apotex, Inc., 480 F.3d 1348 (Fed. [read post]
Patently-O - https://patentlyo.com
Federal Court of Appeal Examines the Scope of the Implied License to Use a Patented Article
21 Feb 2024, 4:00 am by Martin Kratz
Novopharm Ltd., [1998] 2 S.C.R. 129, 161 DLR (4th) 1, Apotex Inc. v. [read post]
Slaw - http://www.slaw.ca/
Obviousness: Is a Reasonable Expectation of Success Sufficient
19 Feb 2024, 12:55 pm by Dennis Crouch
Altoona Publix Theatres, Inc. v. [read post]
Patently-O - https://patentlyo.com
Vanda Seeks Supreme Court Review on Lower Standard for Obviousness
23 Jan 2024, 3:43 am by Dennis Crouch
Apotex (Fed. [read post]
Patently-O - https://patentlyo.com
Double Patenting Again
19 Jan 2024, 4:00 am by Alan Macek
In other contexts, there have been concerns that double patenting may increase burdens under the Notice of Compliance regime for pharmaceuticals – see for example, Glaxosmithkline Inc. v Apotex Inc, 2003 FCT 687 at 90: “The existence of additional patents allows the patent-holder to bring additional applications, thereby obtaining multiple injunctive periods. [read post]
Slaw - http://www.slaw.ca/
When is the use of a product a “substantial noninfringing use” for purposes of Section 271(c)?
11 Dec 2023, 7:43 am by Holman
Apotex Inc., 790 F. [read post]
Patently-O - https://patentlyo.com
A Difficult Test for Inducing Patent Infringement
1 Dec 2023, 4:00 am by Martin Kratz
Les Produits Gilbert Inc., 2008 FCA 35, 67 C.P.R. (4th) 161, para. 13. [3] See Apotex Inc. v. [read post]
Slaw - http://www.slaw.ca/
How to Check if Your Eye Drops Have Been Recalled Due to Contamination
31 Oct 2023, 6:31 am by Searcy Law
Puriton (Kadesh Inc.) [read post]
Searcy Mass Tort - https://searcymasstort.com/blog/
How to Check if Your Eye Drops Have Been Recalled Due to Contamination
31 Oct 2023, 6:31 am by Searcy Law
Puriton (Kadesh Inc.) [read post]
Searcy Denney Scarola Barnhart & Shipley PA Blog - http://www.searcylaw.com/blog/
How to Check if Your Eye Drops Have Been Recalled Due to Contamination
31 Oct 2023, 6:31 am by Searcy Law
Puriton (Kadesh Inc.) [read post]
Searcy Law Blog - http://www.searcylaw.com/what-you-should-know/practice-area-blog/
The Most Common Types of Contaminants Found in Eye Drops
27 Oct 2023, 6:17 am by Searcy Law
On March 2, 2023, Apotex Corp. issued a recall due to “cracks that have developed” in some of the bottles used to store its Apotex-brand eye drops. [read post]
Searcy Law Blog - http://www.searcylaw.com/what-you-should-know/practice-area-blog/
The Most Common Types of Contaminants Found in Eye Drops
27 Oct 2023, 6:17 am by Searcy Law
On March 2, 2023, Apotex Corp. issued a recall due to “cracks that have developed” in some of the bottles used to store its Apotex-brand eye drops. [read post]
Searcy Denney Scarola Barnhart & Shipley PA Blog - http://www.searcylaw.com/blog/
The Most Common Types of Contaminants Found in Eye Drops
27 Oct 2023, 6:17 am by Searcy Law
On March 2, 2023, Apotex Corp. issued a recall due to “cracks that have developed” in some of the bottles used to store its Apotex-brand eye drops. [read post]
Searcy Mass Tort - https://searcymasstort.com/blog/
FDA Denies Vanda’s Citizen Petitions Regarding the Need for Braille Labeling for Tasimelteon Generics
17 Aug 2023, 9:00 pm by Kurt R. Karst
Tobolowsky —In January 2023, Vanda Pharmaceuticals, Inc. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
Canadian Patent Law Update: Declarations, Limitation Periods, and General Releases
1 Aug 2023, 11:47 am by freda
Canadian Energy Services L.P., 2023 FC 906 at para. 20).[5] Apotex Inc v Wellcome Foundation Ltd, [2001] 1 FC 495 (FCA). by Pablo Tseng and Anica Villamayor (Summer Law Student) A Cautionary Note The foregoing provides only an overview and does not constitute legal advice. [read post]
McMillan Publications - https://mcmillan.ca/insights/publications/
Arbutus Biopharma Corporation, FKA Protiva Biotherapeutics, Inc., v. Modernatx, Inc., FKA Moderna Therapeutics, Inc. No. 2020-1183 (Fed. Cir. April 11, 2023)
31 Jul 2023, 1:47 pm by Evan Lim
Apotex Corp., 403 F.3d 1331, 1343–44 (Fed. [read post]
Intellectual Property Law Blog - http://www.intellectualpropertylawblog.com/
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2023)
11 Jun 2023, 8:17 pm by Patent Docs
Teva Pharmaceuticals USA, Inc. [read post]
Patent Docs - http://www.patentdocs.org/
Counterclaim Against Non-Asserted Claims Is Permitted as of Right Under the Patented Medicines (NOC) Regulations
12 Apr 2023, 4:00 am by Martin Kratz
Sandoz Canada Inc., 2023 FC 243 at para 6 quoting from the Regulatory Impact Analysis Statement, (2017) Canada Gazette, Part 1, Vol 151, No 28 at 3317. [3] See Section 7(1)(d), Patented Medicines (NOC) Regulations. [4] See Section 6(3), Patented Medicines (Notice of Compliance) Regulations, subsections (a0 and (b) provide for a counterclaim against asserted claims in a patent or in a certificate of supplementary protection respectively. [5] See Janssen Inc v Apotex… [read post]
Slaw - http://www.slaw.ca/